Early data from the DAISY II study demonstrating T-DXd activity in 31% of patients with HER2-null advanced breast cancer raises the question of whether this agent acts altogether independently of HER2 binding, or whether more sensitive tissue measures of HER2 would further stratify response13. This evidence concerns the gene ERBB2 and breast carcinoma.